These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20849385)

  • 1. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells.
    Kosova B; Tezcanli B; Ekiz HA; Cakir Z; Selvi N; Dalmizrak A; Kartal M; Gunduz U; Baran Y
    Leuk Lymphoma; 2010 Oct; 51(10):1895-901. PubMed ID: 20849385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
    Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
    Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells.
    Dinis J; Silva V; Gromicho M; Martins C; Laires A; Tavares P; Rendeiro P; Torres F; Rueff J; Rodrigues A
    Leuk Lymphoma; 2012 Oct; 53(10):2004-14. PubMed ID: 22475343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.
    Kaymaz BT; Selvi N; Gündüz C; Aktan C; Dalmızrak A; Saydam G; Kosova B
    Ann Hematol; 2013 Jan; 92(2):151-62. PubMed ID: 23053176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
    Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
    Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hydrolysed products of iridoid glycosides can enhance imatinib mesylate-induced apoptosis in human myeloid leukaemia cells.
    Kim MB; Kim C; Chung WS; Cho JH; Nam D; Kim SH; Ahn KS
    Phytother Res; 2015 Mar; 29(3):434-43. PubMed ID: 25583173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
    Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
    Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].
    Liu YY; You LS; Qian WB; Tong Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):473-8. PubMed ID: 23086637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells.
    Solmaz S; Adan Gokbulut A; Cincin B; Ozdogu H; Boga C; Cakmakoglu B; Kozanoglu I; Baran Y
    Nutr Cancer; 2014; 66(4):599-612. PubMed ID: 24669768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
    Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
    Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
    Mencalha AL; Du Rocher B; Salles D; Binato R; Abdelhay E
    Cancer Chemother Pharmacol; 2010 May; 65(6):1039-46. PubMed ID: 19701750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
    BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
    Meng Y; Li Y; Li J; Li H; Fu J; Liu Y; Liu H; Chen X
    Leuk Lymphoma; 2007 Nov; 48(11):2204-12. PubMed ID: 17926190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Suppression of NAMPT expression enhances the sensitivity of K562 cells to imatinib and its relative mechanism].
    Lin PP; Bai XJ; Yue ZX; Yan SF; Li ZW; Gao C; Mei YY; Wang KL; Li WJ; Ding W; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):235-41. PubMed ID: 22541073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.